User:Mr. Ibrahem/Inebilizumab

Inebilizumab, sold under the brand name Uplizna, is a medication used to treat neuromyelitis optica spectrum disorder (NMOSD) due to antibodies against aquaporin 4. It is given by gradual injection into a vein.

Common side effects include urinary tract infection and joint pain. Other side effects may include infusion reactions and infections. Use in pregnancy may harm the baby. It is a monoclonal antibody that binds to CD19 on B lymphocytes and results in their breakdown.

Inebilizumab was approved for medical use in the United States in 2020. In the United States it costs about 137,000 USD per dose as of 2021. It is not commercially avaliable in the United Kingdom or Europe as of 2021.